Qiagen NV
Research Qiagen NV (QGEN) on Bullrun: valuation model: 7.7% undervalued, market cap USD 9.37B, P/E 23.0, dividend yield 0.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerQGEN
- ExchangeNYSE
- CountryNetherlands
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal7.7% undervalued
- Market capUSD 9.37B
- P/E23.0
- Dividend yield0.8%
- Financial periodQ2 2026
- RevenueUSD 535.04M
- Net incomeUSD 103.40M
- Free cash flowUSD 157.32M
- Gross margin63.6%
Valuation Snapshot
Bullrun's latest valuation model marks Qiagen NV as 7.7% undervalued; latest market cap is USD 9.37B; P/E is 23.0; dividend yield is 0.8%.
Peer valuation comparison
Latest P/E is 23.05x versus a Healthcare sector median of 24.64x (6.5% below).
Latest dividend yield is 0.77% versus a Healthcare sector median of 1.83% (57.8% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.09B | USD 436.97M | USD 615.21M | 61.9% | 2 | USD 838.62M | USD 1.44B | USD 3.92B |
| FY2024 | USD 1.98B | USD 157.10M | USD 639.78M | 48.6% | 0.7 | USD 663.03M | USD 1.24B | USD 3.70B |
| FY2023 | USD 1.97B | USD 484.81M | USD 451.38M | 62.5% | 2.1 | USD 667.32M | USD 867.77M | USD 3.87B |
| FY2022 | USD 2.14B | USD 575.66M | USD 694.78M | 64.2% | 2.5 | USD 730.27M | USD 1.42B | USD 3.39B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 9.37B | 23.0 | 0.8% | 0.35 |
| 2025 | 2025-12-31 | USD 9.26B | 22.0 | 0.6% | 0.25 |
| 2024 | 2024-12-31 | USD 9.14B | 114.2 | 3.0% | 1.32 |
| 2023 | 2023-12-29 | USD 8.88B | 29.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.17B | 24.1 | n/a | n/a |
| 2021 | 2021-12-31 | USD 11.31B | 24.4 | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.35 USD, yield 0.8%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.25 USD |
| FY2024 | 1.32 USD |
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids;
ETFs that hold Qiagen NV
Qiagen NV is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares TecDAX UCITS ETF (DE) | 6.15% | 0.51% |
| Amundi TecDAX UCITS ETF Dist | 6.21% | 0.40% |
| WisdomTree Europe Value UCITS ETF - EUR Acc | 2.43% | 0.25% |
| iShares TecDAX UCITS ETF (DE) Dist | 6.15% | 0.51% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Qiagen NV overvalued or undervalued?
Bullrun's valuation model currently marks Qiagen NV as 7.7% undervalued.
What is Qiagen NV's market cap?
Qiagen NV's market capitalization is USD 9.37B.
What is Qiagen NV's P/E ratio?
Qiagen NV's price-to-earnings (P/E) ratio is 23.0.
Does Qiagen NV pay a dividend?
Qiagen NV has a dividend yield of 0.8%.
What does Qiagen NV do?
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.